Phase 1 N=35 Probenecid as Medication for Alcohol Use Disorder (PROB)
Alcohol Use Disorder
Primary: Stimulant Effects of Alcohol When Co-administered With Drug or Matching Placebo — 28.23; 25.26; 20.57; 19.56 scores on scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Healthy
Primary: Part1: Area Under the Concentration-time Curve of the Analyte (Rosuvastatin) in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 21.19; 38.85…
Phase 1 N=24 A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food
Healthy
Primary: Area Under the Concentration-time Curve of BI 1358894 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 7360; 14700; 8430; 14900…
Phase 1 N=24 A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men
Healthy
Primary: Percentage of Subjects With Drug Related Adverse Events (AEs). — 0; 0; 16.7; 33.3 Percentage
Phase 1 N=73 A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
Depressive Disorder, Major
Primary: Mean Blood Oxygenation Level Depend (BOLD) Signal % Change in an Emotional Paradigm, Based on the Emotional Faces From the Warsaw Set of Emotional Facial Expression…
Phase 1 N=34 Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants
Healthy Participants
Primary: Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133 — 12.3; 22.7; 44.9; 22.5 μg/mL
Phase 1 N=43 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Number of Reported Dose Limiting Toxicities (DLT) (Part A Only) — 0; 1; 1 dose-limiting toxicities
Phase 1 N=15 A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite…
Phase 1 N=18 A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Bupropion in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2953; 2795 hours *…
Phase 1 N=12 A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.
Respiratory Syncytial Virus Infection
Primary: Maximum Observed Plasma Concentration (Cmax) of Sisunatovir on Day 1 — 80.14 nanogram per milliliter (ng/mL)
Phase 1 N=12 Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder
Autism Spectrum Disorder
Primary: Safety of hCT-MSC Infusion as Measured by Total Number of Infusion Reactions — 1 infusion reactions
Phase 1 N=31 A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
Healthy
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected Using Fridericia's Correction (QTcF) (ΔΔQTcF) — 0.73 milliseconds (msec)
Phase 1 N=16 A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 1358894 in Plasma Over the Time Interval From 0 Extrapolated to Infinity — 1623.89; 3128.75 Nanomoles*Hour per Liter
Phase 1 N=16 A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma — 14.6; 17.1; 48.9…
Phase 1 N=51 APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Myeloid Malignancy
Primary: To Evaluate the Tolerabililty and the Incidence of Treatment-Emergent Adverse Events of Administration of APR 246 in Combination With Venetoclax and Azacitidine in…